192 related articles for article (PubMed ID: 38383773)
1. CD4
Lei X; de Groot DC; Welters MJP; de Wit T; Schrama E; van Eenennaam H; Santegoets SJ; Oosenbrug T; van der Veen A; Vos JL; Zuur CL; de Miranda NFCC; Jacobs H; van der Burg SH; Borst J; Xiao Y
Cell Mol Immunol; 2024 Apr; 21(4):374-392. PubMed ID: 38383773
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
3. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
4. CD4
Lei X; Khatri I; de Wit T; de Rink I; Nieuwland M; Kerkhoven R; van Eenennaam H; Sun C; Garg AD; Borst J; Xiao Y
Nat Commun; 2023 Jan; 14(1):217. PubMed ID: 36639382
[TBL] [Abstract][Full Text] [Related]
5. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
6. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
7. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
8. cDC1 prime and are licensed by CD4
Ferris ST; Durai V; Wu R; Theisen DJ; Ward JP; Bern MD; Davidson JT; Bagadia P; Liu T; Briseño CG; Li L; Gillanders WE; Wu GF; Yokoyama WM; Murphy TL; Schreiber RD; Murphy KM
Nature; 2020 Aug; 584(7822):624-629. PubMed ID: 32788723
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
Wu R; Ohara RA; Jo S; Liu TT; Ferris ST; Ou F; Kim S; Theisen DJ; Anderson DA; Wong BW; Gershon T; Schreiber RD; Murphy TL; Murphy KM
Nat Immunol; 2022 Nov; 23(11):1536-1550. PubMed ID: 36271147
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
[TBL] [Abstract][Full Text] [Related]
12. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
Kamei M; Matsuo K; Yoshida Y; Shimada K; Otsuki M; Fujimoto N; Ishibashi M; Quan YS; Kamiyama F; Hara Y; Takamura S; Nakayama T
Int J Cancer; 2024 Jun; 154(12):2176-2188. PubMed ID: 38346928
[TBL] [Abstract][Full Text] [Related]
14. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
15. Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies.
Noe P; Wang JH; Chung K; Cheng Z; Field JJ; Shen X; Cortesio CL; Pastuskovas CV; Phee H; Tarbell KV; Egen JG; Casbon AJ
Front Immunol; 2023; 14():1272055. PubMed ID: 37942313
[TBL] [Abstract][Full Text] [Related]
16. Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway.
Molina MS; Hoffman EA; Stokes J; Kummet N; Simpson RJ; Katsanis E
PLoS One; 2022; 17(8):e0273075. PubMed ID: 35980974
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy.
Borst J; Busselaar J; Bosma DMT; Ossendorp F
Eur J Immunol; 2021 Aug; 51(8):1911-1920. PubMed ID: 34106465
[TBL] [Abstract][Full Text] [Related]
18. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses.
Ostrowski MA; Justement SJ; Ehler L; Mizell SB; Lui S; Mican J; Walker BD; Thomas EK; Seder R; Fauci AS
J Immunol; 2000 Dec; 165(11):6133-41. PubMed ID: 11086046
[TBL] [Abstract][Full Text] [Related]
19. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.
Lu Z; Yuan L; Zhou X; Sotomayor E; Levitsky HI; Pardoll DM
J Exp Med; 2000 Feb; 191(3):541-50. PubMed ID: 10662799
[TBL] [Abstract][Full Text] [Related]
20. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4
Mattiuz R; Brousse C; Ambrosini M; Cancel JC; Bessou G; Mussard J; Sanlaville A; Caux C; Bendriss-Vermare N; Valladeau-Guilemond J; Dalod M; Crozat K
Clin Transl Immunology; 2021; 10(7):e1305. PubMed ID: 34277006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
